

## Key Figures (US GAAP; unaudited)

Due to the separate financing of Fresenius SE and Fresenius Medical Care, we have prepared the following overview for information purposes for our debt investors.

The overview includes key figures of the Fresenius Group before consolidation of Fresenius Medical Care as of March 31, 2009.

in million €	Q1 2009 (unaudited)	Q1 2008 (unaudited)
<b>Sales</b>	<b>1,417</b>	1,131
<b>EBITDA</b>	<b>230</b>	159
Depreciation and amortization	-55	-41
<b>EBIT</b>	<b>175</b>	118
Net interest	-88	-29
Other financial result	77	0
Income before income taxes	164	89
Income taxes	-45	-27
less noncontrolling interest	-8	-7
<b>Net income attributable to Fresenius SE, adjusted <sup>1)</sup></b>	<b>57</b>	55
<b>Net income attributable to Fresenius SE</b>	<b>111</b>	55

in million €	Q1 2009	Q1 2008
Investment in property, plant and equipment (gross)	42	48
Acquisitions (gross)	82	166
Operating cash flow	63	150
Debt <sup>2)</sup>	4,995	4,710
Net debt <sup>2)</sup>	4,741	4,499
Net debt/EBITDA <sup>2) 3)</sup>	4.5	4.5
EBITDA/Interest <sup>2) 3)</sup>	2.9	2.9

<sup>1)</sup> adjusted for the effects of mark-to-market accounting of the Mandatory Exchangeable Bonds (MEB) and the Contingent Value Rights (CVR) relating to the acquisition of APP Pharmaceuticals.

<sup>2)</sup> 2008: December 31

<sup>3)</sup> 2008 pro forma APP